JAMP FEBUXOSTAT 80 MG
FEBUXOSTAT : 80 MG · DIN 02490870 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP FEBUXOSTAT?
JAMP FEBUXOSTAT 80 MG contains FEBUXOSTAT : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02490870, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Feb-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP FEBUXOSTAT used for?
JAMP Febuxostat (febuxostat) is indicated to lower serum uric acid levels in patients with gout who have an inadequate response or intolerance to allopurinol, or for whom treatment with allopurinol is inappropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02490870 |
|---|---|
| Brand name | JAMP FEBUXOSTAT |
| Generic / active ingredient | FEBUXOSTAT : 80 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 80 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M04AA03 FEBUXOSTAT |
| AHFS class | 92:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Feb-2020 |
| Original market date | 2020-02-25 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code M04AA03 FEBUXOSTAT. 6 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-FEBUXOSTAT | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02533243 |
| FEBUXOSTAT | 80 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02539837 |
| M-FEBUXOSTAT | 80 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02549425 |
| MAR-FEBUXOSTAT | 80 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02473607 |
| TEVA-FEBUXOSTAT | 80 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02466198 |
| ULORIC | 80 MG | TABLET | TAKEDA CANADA INC | CANCELLED POST MARKET | DIN 02357380 |
Who else supplies FEBUXOSTAT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FEBUXOSTAT appears in 164 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.